A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2263-2276

  Kallen, Karl Josef ^a   Heidenreich, Regina ^a   Schnee, Margit ^a   Petsch, Benjamin ^a   Schlake, Thomas ^a   Thess, Andreas ^a   Baumhof, Patrick ^a   Scheel, Birgit ^a   Koch, Sven D ^a   Fotin Mleczek, Mariola ^a  

^a CureVac GmbH   (Germany)

Author keywords

RNA; Vaccines

Indexed keywords

ADENOSINE; CARCINOEMBRYONIC ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOSINE; GUANOSINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; INFLUENZA VACCINE; MESSENGER RNA; NEW DRUG; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA VACCINE; RNACTIVE; SELF ADJUVANTED RNA VACCINE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; URIDINE;

ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG ADMINISTRATION ROUTE; DRUG TARGETING; EFFECTOR CELL; GENE TECHNOLOGY; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; LIPOSOMAL DELIVERY; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; RNA IMMUNIZATION; TH1 CELL; TH2 CELL; VIRUS STRAIN;

RNA; VACCINES;

CANCER VACCINES; HUMANS; RNA; TOLL-LIKE RECEPTOR 7; VACCINATION; VIRAL VACCINES;

EID: 84885113945     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25181     Document Type: Review

References (35)

1. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011;11:865-72; PMID:22051890
2. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8; PMID: 1690918; http://dx. doi.org/10.112 6/science.1690918
3. Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet JG, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993;23:1719-22; PMID:8325342; http://dx.doi.org/10.1002/eji.1830230749
4. Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995;55:1397-400; PMID:788234l
5. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000;30:1-7; PMID: 10602021; http://dx.doi.org/10.1002/1521-4141 (200001) 30:1<1::AID-IMMU1>3-O. CO;2-#
6. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004;4:1285-94; PMID: 15268662; http://dx.doi. Org/10.1517/l4712598.4.8.1285
7. Pascolo S. Vaccination with messenger RNA. Methods Mol Med 2006;127:23-40; PMID:16988444
8. Ulmer JB, Mason PW, Geall A, Mandl CW RNA-based vaccines. Vaccine 2012;30:4414-8; PMID:22546329; http://dx. doi.org/10.1016/j. vaccine.2012.04.060
9. Gust TC, Zenke M. RNA transfer and its use in dendritic cell-based immunotherapy. Expert Opin Biol Ther 2005;5:173-81; PMID: 15757379; http://dx.doi.org/10.1517/14712598.5.2.173
10. Probst J, Fotin-Mleczek M, Schlake T, Thess A, Kramps T, Kallen KJ. Messenger RNA vaccines. Springer Verlag Wien, 2012.
11. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol 2012;9:1319-30; PMID:23064118; http://dx.doi.org/10.4161/ rna.22269
12. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004;61:2418-24; PMID: 15378210; http://dx.doi.org/10.1007/s00018-004-4255-0
13. Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004;34:537-47; PMID: 14768059; http://dx.doi.org/10.1002/eji.200324198
14. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, et al. Toll-like receptor-dependent activation of several human blood cell types by protaminecondensed mRNA. Eur J Immunol 2005;35:1557-66; PMID: 15832293; http://dx.doi.org/10.1002/eji.200425656
15. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006;36:2807-16; PMID: 17013976; http://dx.doi.org/10.1002/eji.200635910
16. Banerjee AK. 5'-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev 1980;44:175-205; PMID:6247631
17. Wickens M. How the messenger got its tail: addition of poly (A) in the nucleus. Trends Biochem Sci 1990;15:277-81; PMID: 1974368; http://dx.doi.org/10. 1016/0968-0004 (90) 90054-F
18. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010;70:9031-40; PMID:21045153; http://dx.doi.org/10.1158/0008-5472. CAN-10-0699
19. Kuhn AN, Diken M, Kreiter S, Vallazza B, Tiireci O, Sahin U. Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biol 2011;8:35-43; PMID:21289486; http://dx. doi.org/10.4161/rna.8.1.13767
20. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011;34:1-15; PMID:21150709; http://dx.doi.org/10.1097/CJI.0b013e3181f7dbe8
21. Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WP, et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 2011;8:627-36; PMID:21654214; http://dx.doi.org/10.4161/rna. 8.4.15 394
22. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-70; PMID: 15723075; http://dx.doi.org/10.1038/nml 191
23. Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Tiireci O, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011;18:702-8; PMID:21368901; http://dx.doi.org/10.1038/gt.2011.17
24. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med 2012;14:428-39; PMID: 22262664; http://dx.doi.org/10.1002/jgm.2605
25. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012;30:1210-6; PMID:23159882; http://dx.doi.org/10.1038/nbt.2436
26. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309:13-7; PMID:6602294; http://dx.doi.org/10.1056/ NEJM198307073090103
27. Ulmer J B, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9; PMID:8456302; http://dx.doi.org/10.1126/ science. 8456302
28. Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007;18:529-36; PMID: 18083548; http://dx.doi.org/l 0.1016/j.copbio.2007.11.002
29. Chaloupka I, Schuler A, Marschall M, Meier-Ewert H. Comparative analysis of six European influenza vaccines. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 1996;15:121-7.
30. Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012;72:1661-71; PMID:22337996; http://dx.doi.org/l 0.115 8/0008-5472. CAN-11-2957
31. Kreiter S, Diken M, Selmi A, Diekmann J, Attig S, Hiisemann Y, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res 2011;71:6132-42; PMID:21816907; http://dx.doi.org/10.1158/0008-5472. CAN-11-0291
32. Sebastian M, Von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, et al. Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial. J Clin Oncol 2011;29:2584.
33. Sebastian M, Von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, et al. Messenger RNA vaccination and B-cell responses in NSCLC patients. J Clin Oncol 2012;30:2573; PMID:22565006
34. Kiibler H, Maurer T, Stenzl A, Feyerabend S, Steiner U, Schostak M, et al. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. J Clin Oncol 2011;29:4535.
35. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61